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Letters to the EditorSAFETY OFAPROTININ IN
ADULT CARDIAC
SURGERY: REVISITING THE
VALIDITY OFA MIXED-
TREATMENT COMPARISON
META-ANALYSIS
To the Editor:
I read with great interest the
article by Howell and colleagues1 on
a mixed-treatment meta-analysis of
trials of aprotinin in adult cardiac sur-
gery drawn from the publications iden-
tified in a previous Cochrane review.2
In their publication, Howell and col-
leagues1 concluded that this reanalysis
demonstrated no increase in the risk of
mortality for patients treated with
aprotinin relative to either placebo or
other antifibrinolytic agents.
Recently, a variety of sophisticated
statistical methods have been pro-
posed to provide direct and indirect
estimates of comparative treatment
effects. Such evidence synthesis ap-
proach can be informative when rela-
tive treatment effects are consistent
across all trials and there is high
agreement between direct and indirect
estimates. To achieve relevant clinical
impact, however, the validity of
methods must convince both the epi-
demiologic and clinical audiences. I
believe that the limitations described
here question the validity of the pub-
lished results1 and thus their utility
in guiding medical decision making.
First, Howell and colleagues1 did
not adequately discuss the statistical
models (and their limitations) for esti-
mating indirect and mixed-treatment
comparisons, implying that they could
provide more accurate and precise re-
sults than direct pairwise compari-
sons. Indirect and mixed-treatment
comparisons are based on assump-
tions of transitivity (if A is much bet-
ter than B, and B is better than C, then
A is assumed to be better than C) and
consistency (agreement between vari-
ous sources of evidence), assumptions
that can be verified conceptually and
epidemiologically but are, however,
subject to substantial uncertainty.610 The Journal of Thoracic and CConsideration of these aspects will
naturally lead clinicians and system-
atic reviewers in evaluating the under-
lying assumptions, will encourage
exploration of potential disagree-
ments between trials thus giving better
insight into the research question, and
will add transparency to the choices
being made regarding comparative
data synthesis.3
Second, bias in small trials of antifi-
brinolytics is notorious, and often
selective reporting is intractable. Vari-
ous approaches to deal with publica-
tion bias and to account for effect
modifiers or to evaluate the risk of
bias have been developed.3 Indeed,
the reporting bias effect in mixed-
treatment comparisons may differ
from that in conventional meta-analy-
ses.4 Howell and colleagues1 failed
to mention, however, that the Co-
chrane review2 they used for their
mixed-treatment comparisons noted
evidence of publication bias in trials
testing aprotinin. This led to a probable
overestimation of the blood-sparing
effect of the drug, thus bringing into
question the results provided in Fig-
ure 5 in the article of Howell and col-
leagues.1 Conversely, no publication
bias was reported in relation to clinical
outcomes of death,2 but a trend was
seen toward increased mortality
among those patients receiving aproti-
nin relative to those who received tra-
nexamic acid or ε-aminocaproic acid.
Third, I believe that the main lim-
itation of the meta-analysis by
Howell and colleagues is the rela-
tively small number of deaths (highly
dependent on the Blood Conservation
Using Antifibrinolytics in a Random-
ized Trial [BART] study), which
clearly limits the power of the analy-
ses. Along the same line, antifibrino-
lytic trials have been conducted for
different durations, explaining the
variation in amounts of evidence as
a result of variations across trials in
characteristics of cardiac patients,
surgical procedures, or outcome as-
sessment5 (eg, mortality duringardiovascular Surgery c February 2013surgery, in-hospital mortality, 30-
day mortality).
In summary, I believe that Howell
and colleagues have unintentionally
overinterpreted the evidence and
ignored assumptions inherent in
mixed-treatment meta-analysis. This
has led to overly categoric conclu-
sions from an interesting approach
fraught with uncertainty.
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We thank Dr Catala-Lopez for his
interest in our study.1 In reply to
Letters to the Editorsome of the methodologic issues
raised, we point out that randomized
trials minimize bias because, as
Fisher noted, the simple act of ran-
domization assures the internal valid-
ity of the test for significance.2 In
other words, randomization allocates
subjects on the basis of the play of
chance and thus enables us to con-
sider just 2 orthogonal alternative ex-
planations for any treatment effect
observed; that is, that the difference
in treatment effect is due to chance
or is due to the experimental thera-
pies. Dr Catala-Lopez is presumably
aware of the design advantages of
the randomized trials through his reg-
ulatory work.
Mixed treatment analyses are
commonly used by technology assess-
ment groups, such as the National In-
stitute for Clinical Excellence in the
United Kingdom, to summarize data
on several treatments for a common
condition.3 Our work builds on
the thoughtful conventional meta-
analysis from which our data were
drawn and confirms that no adverse
treatment effect associated with apro-
tinin is found even when we take this
approach.
Small-study bias is less likely to be
an issue when it comes to comparative
studies; in any case, however, it is
likely to be of smaller magnitude
than the bias in nonrandomized stud-
ies. Thus Catala-Lopez seems to be
missing the point; however we ana-
lyze the data from randomized trials,
we cannot find a problem associated
with aprotinin use, and the regulatory
concern and action surrounding this
potentially useful agent thus has not
been to the benefit of patients.
Finally, we wonder whether em-
ployment by a regulatory body that
made an incorrect decision to with-
draw the use of aprotinin does consti-
tutes a declarable conflict of interest.
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To the Editor:
We read with great interest the arti-
cle by Chaudhuri and colleagues1
about carbon dioxide insufflation in
open-chamber cardiac surgery. Insuf-
flation of carbon dioxide in the
pericardial cavity to prevent the de-
velopment of cardiac or neurologic
damage from air embolism has been
mentioned in the literature since
1967.2 Manual deairing proved to be
highly inefficient in the elimination
of air emboli even when it was
done with very meticulous technique.
Improvement was seen when echocar-
diography was introduced as a stan-
dard clinical method for recording
air bubbles in the process of deairing
heart cavities, with the deairing
procedure performed under visual
control.3of Thoracic and Cardiovascular SurgeWith the help of transcranial
Doppler ultrasonography, it was
found that despite the detailed deair-
ing, one of the biggest sources of air
embolism occurs during distribution
of blood from the heart–lung machine
to the empty, beating heart, when the
heart begins to eject actively.4 In that
respect the article provides the neces-
sary safety guidance on the duration
of the deairing procedure with and
without carbon dioxide insufflation
in pericardial cavity without fear for
the development of neurocognitive
damage. In addition to age, hyper-
cholesterolemia, aortic burden, and
coronary artery disease, however,
neurologic outcome after cardiac sur-
gery is also influenced by other fac-
tors as a consequence of applied
surgical technique.
We do not want to split hairs, but re-
marks that we discuss here are regu-
larly the subject of fierce debate at
our clinic. In addition to aortic burden,
surgical manipulation on the aorta has
significant impact on development of
neurologic sequelae or recovery from
the same. Patients who underwent sur-
gical myocardial revascularization as
additional procedure with open heart
cavities make up a quarter of patients
in the study of Chaudhuri and col-
leagues.1 The increased number of
surgical manipulations on the aorta
as a result of the revascularization
strategy, single or multiple clamping
applied during the formation of the
proximal anastomosis, could lead to
a higher degree of neurocognitive im-
pairments.5 This concern is especially
pronounced in light of the multicenter
character of study, which did not al-
low the possibility of selecting the sur-
gical techniques that would be used in
the study, because some surgeons
probably had rigid personal views
about issues of technique. Occurrence
of gross neurologic outcomes, such as
stroke, transient ischemic attack, or
delirium, was not described in the
postoperative period, although such
could be expected in a study of this
size on the basis of previous studies.6ry c Volume 145, Number 2 611
